NCT05768139 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05768139
Title	First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors (PIKALO-1)
Acronym	PIKALO-1
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Eli Lilly and Company
Indications	endometrial cancer head and neck squamous cell carcinoma estrogen-receptor positive breast cancer Advanced Solid Tumor progesterone-receptor positive breast cancer Her2-receptor negative breast cancer female reproductive organ cancer
Therapies	Exemestane + Ribociclib + STX-478 Exemestane + Palbociclib + STX-478 Anastrozole + Ribociclib + STX-478 Anastrozole + Palbociclib + STX-478 Letrozole + Ribociclib + STX-478 Letrozole + Palbociclib + STX-478 Fulvestrant + Ribociclib + STX-478 Fulvestrant + Palbociclib + STX-478 Fulvestrant + STX-478 STX-478
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| IRL \| FRA \| ESP \| DEU \| BEL

Additional content available in CKB BOOST